Health Canada. “Approval of SATIVEX® with Conditions Fact Sheet.” Last accessed 16 December 2005. Available at xxxx://xxx.xx-xx.xx.xx/dhp-mps/prodpharma/notices-avis/conditions/sativex_factsheet_e.html. PRESS RELEASE — UK VERSION GW and Otsuka Announce Major Long Term Strategic Cannabinoid Alliance London, UK; Princeton, NJ, USA; Tokyo, Japan; 14 February 2007: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have entered into a major long term strategic cannabinoid alliance. The relationship has commenced with the signing of an exclusive license and development agreement to develop and market Sativex®, GW’s lead product, in the United States. The companies are also in detailed discussions with a view to entering into a cannabinoid research collaboration in the field of Central Nervous System (CNS) disorders and cancer treatment in order to research, develop and commercialize a range of other early stage cannabinoid product opportunities. The Otsuka Pharmaceutical Group has placed significant emphasis on the research of CNS disorders for the past 27 years. Otsuka’s lead product in the field of CNS ranks among the top seven product launches in industry history and the No. 1 product launch since 2002. Worldwide revenues from this product increased from $1.3bn in 2005 to over $1.9bn in 2006. The Group is privately owned, comprises 87 companies and employs approximately 27,000 people in 17 countries and regions worldwide. It earned revenues of $6.8 billion in fiscal 2005, ranking it the 26th largest pharmaceutical company in the world(2). Otsuka is continuing to expand its CNS specialty sales force presence in the US.
Health Canada. As of April 30, 2018, all Material Contracts and written correspondence or written notice received from Health Canada in relation to any Authorization from Health Canada have been provided to the Buyer or made available in the Company Data Room.
Health Canada. All written correspondence or written notice received from Health Canada in relation to the Required Licenses have been made available to the Purchaser.
Health Canada. Publication xxxx://xxx.xx-xx.xx.xx/hecs-sesc/tsri/tsri.htm Summaries of individual research projects are provided on the web-site. Comments For the purposes of this UNEP survey; 5 TSRI projects out of the total 97 projects have been selected for detailed description. Separate Annex 1 forms have been completed for the global monitoring information for each of the 5 projects. This form covers Project 1; TSRI #11; Sources of Agrochemicals to the Atmosphere and Delivery to the Canadian Environment. Project Summary: Many organochlorine pesticides (OCPs) have been banned for decades in Canada and the U.S.; but are still present in air from the Great Lakes and arctic regions. OCPs that are typically found in air include DDT; dieldrin; chlordane and toxaphene. What is the source of these chemicals today? Are they carried through the air from countries where they are still used; or recycled into the atmosphere from contaminated soil and water? Project TSRI #11 addresses this central question in several ways. Agricultural soils are surveyed in selected areas of Canada and the U.S. where OCPs were used in the past to determine the amount available to be released into the atmosphere. Estimates of releases are obtained by measuring levels of pesticides in air above agricultural soils and through computer simulations of pesticide emissions from soil. A case study is being done of pesticide transport in an Ontario watershed which is known to be contaminated with DDT. Measurements are carried out in the southern U.S. and Mexico to determine whether transport from these suspected source regions is bringing OCPs into Canada. Emission and transport are also determined for certain compounds that are currently used in agriculture. Results of the project will provide a better understanding of where airborne pesticides come from and how they are transported to Canadian ecosystems.
Health Canada. Publication xxxx://xxx.xx-xx.xx.xx/tsri
Health Canada. Publication xxxx://xxx.xx-xx.xx.xx/tsri Comments For the purposes of this UNEP survey, 5 TSRI projects out of the total 97 projects have been selected for detailed description. Separate Annex 1 forms have been completed for each of the 5 projects. This form covers Project 3; TSRI #207: Toxaphene in the St. Xxxxxxxx River Marine Ecosystem: State of Contamination, Ecosystem Toxicology and Human Health. Toxaphene is a complex mixture of chlorinated camphenes which is toxic and persistent in the environment. It has been studied in Arctic marine environments and Canadian lakes. However in eastern Canada toxaphene has not been the subject of significant research even though belugas in the St. Xxxxxxxx river basin demonstrate toxaphene concentrations among the highest observed in marine mammals. At present very little is known about the dispersion of this Persistent Organic Pollutant (POP) in the marine ecosystem of the St. Xxxxxxxx. In addition the toxicological risks posed to fish and to top predators including humans are currently unknown. To fill these gaps TSRI Project 207 titled: Toxaphene in the St. Xxxxxxxx River Marine Ecosystem: State of Contamination Ecosystem Toxicology and Human Health will evaluate : 1) dispersion of toxaphene in the St. Xxxxxxxx marine ecosystem; and 2) some ecotoxicological risks to marine organisms and humans associated with Toxaphene in the St. Xxxxxxxx marine ecosystem. Contact Xx Xxxxxxx Tremblay 000 000 0000 xxxxxxx.xxxxxxxx@hc- xx.xx.xx Canada Title Objective(s) Toxic Substances Research Initiative (TSRI). Project # 4. The Toxic Substances Research Initiative (TSRI), is a $40 million program managed by Health Canada and Environment Canada, which was launched in 1998. The TSRI reinforces the federal government's commitment to enhance the health and environment of Canadians, through funding a variety of research projects on toxic substances. The research funded by the TSRI will help to protect the health and environment of Canadians by gathering an improved knowledge of toxic substances, and their adverse effects. The TSRI enhances existing research partnerships and fosters the development of new collaborations between non-government and federal government researchers, to focus on emerging issues not adequately addressed by existing research. Canadians will benefit directly from this investment as it will strengthen the government's capacity to protect their health and environment in a socially and economically responsible man...
Health Canada. 2) University of Ottawa, The Loeb Research Institute
Health Canada. All of the Redecan Licences and all other material licenses, and all material correspondence or material written notices received from Health Canada in relation to any Acquired Entity have been provided to or made available to the Purchaser. Except as set out in Section 4.19 of the Sellers’ Disclosure Letter, no consent, waiver or approval is required to be obtained in order to maintain the Redecan Licences in full force and effect immediately upon the consummation of the Transactions.
Health Canada. All of the Zenabis Licences are listed in Section 16 of the Disclosure Letter. All of the Zenabis Licences and all other material licenses, and all material correspondence or material written notices received from Health Canada in relation to Company have been provided to or made available to the Purchaser. No consent, waiver or approval is required to be obtained in order to maintain the Zenabis Licences in full force and effect immediately upon the consummation of the Arrangement.
Health Canada. All of the Newstrike Licences and all material correspondence or material written notices received from Health Canada in relation to Company have been provided to or made available to the Purchaser.
